-
Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaDaiichi Sankyo2021-04-07 09:27:33Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia
-
DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal CancerDaiichi Sankyo2021-04-06 09:43:21DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal
-
DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Small Cell Lung CancerDaiichi Sankyo2021-03-29 09:32:36DESTINY-Lung02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Mutated Metastatic Non-Small Cell
-
Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with Relapsed/Refractory B-Cell LymphomaDaiichi Sankyo2021-02-24 08:52:39Daiichi Sankyo and LYSA-LYSARC-CALYM Enter Research Collaboration for Valemetostat in Patients with
-
Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&DDaiichi Sankyo2021-02-22 13:14:52Daiichi Sankyo Appoints Ken Takeshita, MD as Global Head of R&D
-
HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated NSCLCDaiichi Sankyo2021-02-02 16:39:14HERTHENA-Lung01 Phase 2 Study of Daiichi Sankyo’s Patritumab Deruxtecan Initiated in Patients with
-
Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research InstituteDaiichi Sankyo2021-02-02 16:28:25Daiichi Sankyo Initiates Clinical Development of Sixth DXd ADC DS-6000 with Sarah Cannon Research Institute
-
New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutated NSCLC Presented at WCLC 2020Daiichi Sankyo2021-02-02 11:10:14New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutated NSCLC Presented
-
Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung CancerDaiichi Sankyo2021-02-02 11:32:38Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small
-
ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics SocietyDaiichi Sankyo2021-02-02 11:32:52ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics Society
